0.70 USD
↘ 0.03 (3.50%)AT CLOSE (11:59 AM EDT)
PharmaCyte Biotech, Inc. Common Stock
PMCBNASDAQ • USD
0.71
↗ 0.01 (0.71%)
POST MARKET (AS OF 07:10 PM EDT)
Post Market
AS OF 07:10 PM EDT
0.71
↗ 0.01 (0.71%)
Market: CLOSED
Open?$0.73
High?$0.74
Low?$0.67
Prev. Close?$0.73
Volume?196.6K
Avg. Volume?247.4K
VWAP?$0.71
Rel. Volume?0.79x
Bid / Ask
Bid?$0.57 × 100
Ask?$0.83 × 100
Spread?$0.26
Midpoint?$0.70
Valuation & Ratios
Market Cap?7.5M
Shares Out?10.7M
Float?9.5M
Float %?88.3%
P/E Ratio?N/A
P/B Ratio?0.20
EPS?-$0.70
Dividend?2.16%
Ex-Dividend?N/A
PharmaCyte Biotech, Inc. Common Stock (PMCB) is currently trading at $0.70. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Employees
2
Market Cap
7.5M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2003-09-11
Address
3960 HOWARD HUGHES PARKWAY
LAS VEGAS, NV 89169
Phone: (917) 595.2850
LAS VEGAS, NV 89169
Phone: (917) 595.2850
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?71
Piotroski F-Score?0/9Weak
Altman Z-Score?-2.14Distress
Confidence?43%Low
Short InterestLow
Short % of Float?4.96%Low
Short Interest?469.9K
Days to Cover?1.2
Free Float9.5M
Avg Daily Volume382.8K
Settlement Date2026-05-15
Financial Health
Current Ratio?12.33Strong
Quick Ratio?12.33Strong
Cash Ratio?12.02Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?0.20CHEAP▾
Peers100
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?2.4CHEAP▾
Peers100
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-19.6%WEAK▾
S&P8
ROA?-13.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$-12650581
Fundamentals ratios updated end of day